Canaccord lowered the firm’s price target on Biogen (BIIB) to $220 from $265 and keeps a Buy rating on the shares. The firm noted Q1 results beat consensus and they are encouraged by the solid top-line performance, and EPS actually came in higher than had been expected. Execution will remain the key as they expect more focus on growth and the pipeline in 2026.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BIIB: